An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a stem cell therapy (CD34+ cells) to treat patients with refractory angina showed a statistically significant improvement in exercise time as well as a reduction in mortality. Results from “CD34+ Stem Cell Therapy Improves Exercise Time and Mortality in Refractory Angina: A Patient Level Meta-Analysis” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

Peripheral artery disease (PAD) patients who were treated with an anti-inflammatory steroid injected directly into the tissue surrounding their leg artery showed a significant reduction in inflammatory biomarkers, according to new data from the DANCE trial. Results from the trial were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to have atrial fibrillation (AF) either at baseline or new-onset within 30 days after TAVR, according to data from the BRAVO-3 randomized trial. Patients with new-onset AF had a greater than 4-fold greater risk of stroke within 30 days. Results from the trial were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

May 11, 2017 — Biotronik announced U.S. Food and Drug Administration (FDA) approval of the company's MultiPole Pacing (MPP) technology, providing physicians with additional treatment options for heart failure patients who have been non-responsive to cardiac resynchronization therapy (CRT). MPP will be available on new Biotronik CRT defibrillator (CRT-D) systems for patients with heart failure.

A large nuclear cardiology laboratory in Missouri has slashed its average radiation dose by 60 percent in eight years, according to new research presented at ICNC 2017, May 7-9 in Vienna, Austria and published in JACC: Cardiovascular Imaging.1,2 The study in over 18,000 patients showed dose reductions were achieved despite a large number of obese patients.

McKesson Imaging & Workflow Solutions, an industry leader in providing healthcare IT and imaging solutions, is pleased to announce that independent research firm KLAS has named McKesson Radiology a Category Leader in the 2017 Best in KLAS: Software & Services report for the Picture Archiving and Communications Solutions (PACS) (Community Hospital) segment, ranking number-one in the market segment. 

Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier for physicians to more effectively treat atrial fibrillation (AF). When integrated with Abbott's EnSite Precision cardiac mapping system, physicians are able to utilize dual impedance and magnetic technologies to help more precisely model the heart. This integrated system also helps physicians determine where to apply optimal contact force (pressure) when creating a lesion during a cardiac ablation to correct a heart rhythm abnormality. The Sensor Enabled technology allows physicians to create a more detailed heart model during ablation procedures than a catheter without a sensor.

Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm management (CRM) devices with technology that automatically recognizes when a patient enters a magnetic resonance imaging (MRI) environment.

Biotronik announced U.S. Food and Drug Administration (FDA) approval and the launch of Sentus ProMRI, the thinnest quadripolar left ventricular lead available in the United States. This introduction completes Biotronik's second-generation ProMRI lead portfolio, which also includes Solia ProMRI and Plexa ProMRI.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now